A Randomised Multicentre Trial Of Involved Field Radiotherapy Versus Involved Field Radiotherapy Plus Chemotherapy In Combination With Rituximab (Mabthera®) For Stage I – II Low Grade Follicular Lymphoma

For patients with stage I and II low grade follicular lymphoma radiotherapy will cure 40-50% of cases. This study is comparing standard therapy (radiotherapy) and investigational therapy (radiotherapy plus chemotherapy) to see if adding chemotherapy extends the time until the lymphoma progresses in those patient that will not be cured.

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Collaborating Groups

ALLG (NHLLOW 5); Princess Margaret Hospital, Toronto

Final Accrual

150

Closing Date of Accrual

July 2012

Trial Chairperson

A/Prof Michael Mac Manus, Peter MacCallum Cancer Centre, VIC

Trial Contact

Bev.McClure@petermac.org

Clinical Trial Registration

Related Post

26 September, 2026

Trial finds radiation therapy halves risk of brain tumour recurrence after surgery

LATEST NEWS: 26 September 2026 Giving radiotherapy after surgery

17 September, 2026

Meet the TROG Quality Assurance team

TROG UPDATES: 17 September 2026 Our Quality Assurance team